This promotional meeting, sponsored by BeiGene, brought together a group of clinical experts to discuss their experience of treating patients with Waldenstrom’s Macroglobulinaemia using BRUKINSA^®▼ (zanubrutinib), a next generation BTK inhibitor. This meeting involved sharing case studies and discussing the role of BRUKINSA in treatment pathways and hospital protocols. The second part of the meeting focused on the role of BRUKINSA (zanubrutinib) in treating Chronic Lymphocytic Leukaemia (CLL).

Agenda

Recordings

Welcome to “Real world experience treating WM and what’s next for CLL” – Dr Robert Mulrooney

Date of preparation: July 2023. 0723-BRU-PRC-076

Waldenström’s macroglobulinaemia/ lymphoplasmacytic lymphoma: An introduction – Prof George Follows

Date of preparation: July 2023. 0723-BRU-PRC-077

Case-based panel discussion – Dr Pam McKay

Date of preparation: July 2023. 0723-BRU-PRC-078

Case-based panel discussion – Dr Sarah Lawless

Date of preparation: July 2023. 0723-BRU-PRC-079

Case-based panel discussion – Dr Vishal Jayakar

Date of preparation: July 2023. 0723-BRU-PRC-080

BTK inhibitor choices in CLL: What’s next for zanubrutinib in CLL? – Dr Toby Eyre

Date of preparation: July 2023. 0723-BRU-PRC-081

Closing

Date of preparation: July 2023. 0723-BRU-PRC-082